Asset managers ask pharmaceutical companies to stop competing in the hunt for a corona vaccine

Important shareholders in the global pharmaceutical industry, including asset and pension managers, are asking pharmaceutical companies to work together to develop a coronavirus vaccine or treatment.

Photo: Illustration: Dado Ruvic/Reuters/Ritzau Scanpix

The world's largest investors and asset managers are encouraging pharmaceutical companies to work together to develop a corona vaccine to put a stop to the global economic crisis caused by the pandemic, the Financial Times reports.

Blackrock, Fidelity Investments and Fidelity International, Aviva Investors, Janus Henderson and Amundi have all said to the paper that they want pharmaceutical companies to put their rivalries to one side and work together.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Why do Nordic funds have so few female portfolio managers?

Only 16 percent of fund managers in Sweden are women. The figure is 11 percent in Finland, while just 6 percent of fund managers in Denmark and Norway are female. AMWatch has talked to four Nordic women in finance in search of answers regarding this imbalance and hear about their career experiences. 

Fidelity plans to halve CO2 in investment portfolios by 2030

Fidelity International's target will initially be limited to portfolio companies' direct emissions and those that stem from energy the company buys, so-called Scope 1 and Scope 2 emissions. The manager intends to add Scope 3 emissions once it has access to better data.

Further reading

Related articles

Trial banner

Latest news


Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch